Lanell M. Peterson

University of Washington — United States

Medicine · Health Sciences

30h-index4.8kcitations109works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(82), Radiomics and Machine Learning in Medical Imaging(27), Radiopharmaceutical Chemistry and Applications(26), Breast Cancer Treatment Studies(19), Estrogen and related hormone effects(19)

Publications109 total

Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted therapy
European Journal of Nuclear Medicine and Molecular Imaging·2025Open Access
Abstract PS11-05: Novel 4D radiomics applied to dynamic FES PET images to improve prediction of ER-positive breast cancer outcomes for ER-targeted therapy
Clinical Cancer Research·2025
Abstract PS11-01: [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142
Clinical Cancer Research·2025· 1 cited
Clinical utility of [ <sup>18</sup> F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.
Journal of Clinical Oncology·2025
[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer
Molecular Imaging and Biology·2025· 1 citedOpen Access
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
Breast Cancer Research·2025· 1 citedOpen Access
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
2024Open Access
Mise à jour de la tolérance à long terme du bimekizumab chez les patients atteints de spondylarthrite axiale (axSpA) et de rhumatisme psoriasique (RhuPso) : résultats regroupés des études de phase IIb/III
Revue du Rhumatisme·2024
Multimodal serial assessment of neoadjuvant therapy response and recurrence-free survival in locally advanced breast cancer
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
EJNMMI Research·2024· 2 citedOpen Access
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Research Square (Research Square)·2024· 1 citedOpen Access
Tolérance à long terme du bimékizumab chez les patients atteints de spondyloarthrite axiale (axSpA) et de rhumatisme psoriasique (RhPso) : résultats groupés des études de phase IIb/III
Revue du Rhumatisme·2023
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
Breast Cancer Research·2023· 12 citedOpen Access
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Annals of Oncology·2023· 54 citedOpen Access
Supplementary Figure 1A-B from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
2023Open Access
Online supplement from Estrogen Receptor Binding (&lt;sup&gt;18&lt;/sup&gt;F-FES PET) and Glycolytic Activity (&lt;sup&gt;18&lt;/sup&gt;F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER&lt;sup&gt;+&lt;/sup&gt; Breast Cancer
2023Open Access
Supplementary Figure 1A-B from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
2023Open Access
Data from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
2023Open Access
Data from Estrogen Receptor Binding (&lt;sup&gt;18&lt;/sup&gt;F-FES PET) and Glycolytic Activity (&lt;sup&gt;18&lt;/sup&gt;F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER&lt;sup&gt;+&lt;/sup&gt; Breast Cancer
2023Open Access
Data from Estrogen Receptor Binding (&lt;sup&gt;18&lt;/sup&gt;F-FES PET) and Glycolytic Activity (&lt;sup&gt;18&lt;/sup&gt;F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER&lt;sup&gt;+&lt;/sup&gt; Breast Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

David A. Mankoff(31), Hannah M. Linden(22), Kenneth A. Krohn(18), Mark Muzi(16), Brenda F. Kurland(16), Erin K. Schubert(15), Jennifer M. Specht(12), Jeanne M. Link(10), Julie R. Gralow(9), Michael M. Graham(8), John R. Grierson(8), Paul E. Kinahan(8), Janet F. Eary(5), Alena Novakova-Jiresova(5), Vijayakrishna K. Gadi(5), Janet S. Rasey(4), Wui-Jin Koh(4), Margaret L. Evans(4), Robert B. Livingston(4), Lisa K. Dunnwald(4)